Radar Telegram alerts Open Radar

Roche's lung cancer drug extends survival by nearly six months in late-stage trial (RHHBY:OTCMKTS).

Seeking Alpha Markets · Source

Roche's lung cancer drug extends survival by nearly six months in late-stage trial (RHHBY:OTCMKTS).